Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine, Lisaftoclax, and Olverembatinib in Advanced CML and Ph+ AML
NCT06401603Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lisaftoclax and olverembatinib in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events. Started Aug 2024; status: recruiting.
02
Drugs
lisaftoclaxolverembatinib
03
Conditions
chronic myeloid leukemia (CML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06401603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06401603.